VistaGen Therapeutics, Inc. (VTGN) Key Metrics
VTGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.9M
- Enterprise value
- −$14.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.5 10-yr median 96.0
- Price / book
- 0.7 10-yr median 0.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.33
VTGN key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · U.S. dollarsVTGN valuation Price multiples at each fiscal year-end price.
Price / sales−89.2%
17.1
FY2026 · hover or tap a bar for each year
FY2017FY2026
Price / book−44.3%
0.6
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow yield−251.3 pts
−306.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
VTGN returns How much profit the business earns on the capital it uses.
Return on equity−75.9 pts
−131.6%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets−55.4 pts
−104.9%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover+308.6%
0.02
FY2026 · hover or tap a bar for each year
FY2017FY2026
VTGN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+111.8%
$0.03
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$1.83
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow per share
−$1.74
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share−59.1%
$0.93
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+23.3%
38.1M
FY2026 · hover or tap a bar for each year
FY2017FY2026
VTGN financial health Debt, liquidity and how easily interest is covered.
Debt / equity+37.1%
0.03
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt+$34.6M
−$44.4M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−43.6%
3.67
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets+20.2%
0.02
FY2026 · hover or tap a bar for each year
FY2017FY2026
VTGN efficiency & capital use Working capital cycle and where the cash goes.
Capex / revenue−27.4 pts
11.9%
FY2026 · hover or tap a bar for each year
FY2017FY2026
VTGN valuation history
Fiscal year-endToday10-year median
VTGN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VTGN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VTGN cash returned to shareholders
DividendsBuybacksFree cash flow
VTGN price vs earnings per share
Share price at year-endEPS (right axis)
VTGN key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $21.7M | $77.2M | $102.2M | — | — | — | — | — | — | — |
| Enterprise value | −$22.7M | −$1.8M | −$14.9M | — | — | — | — | — | — | — |
| Price / sales | 17.1 | 158.8 | 96.0 | — | — | — | — | — | — | — |
| Price / book | 0.6 | 1.1 | 0.9 | — | — | — | — | — | — | — |
| EV / sales | -17.9 | -3.7 | -14.0 | — | — | — | — | — | — | — |
| Earnings yield | −321.1% | −66.6% | −28.7% | — | — | — | — | — | — | — |
| Free cash flow yield | −306.1% | −54.8% | −25.3% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $0.57 | $2.50 | $5.28 | $3.74 | $37.20 | $63.90 | $13.20 | $38.40 | $27.84 | $58.80 |
| Per share | ||||||||||
| Revenue per share | $0.03 | $0.02 | $0.05 | — | — | — | — | — | — | — |
| Earnings per share | −$1.83 | −$1.67 | −$1.52 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.74 | −$1.36 | −$1.33 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.74 | −$1.37 | −$1.34 | — | — | — | — | — | — | — |
| Cash per share | $1.19 | $2.61 | $6.16 | — | — | — | — | — | — | — |
| Book value per share | $0.93 | $2.28 | $5.90 | — | — | — | — | — | — | — |
| Tangible book value per share | $0.93 | $2.28 | $5.90 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.01 | $0.00 | — | — | — | — | — | — | — |
| Debt per share | $0.03 | $0.05 | $0.11 | — | — | — | — | — | — | — |
| Shares outstanding | 38.1M | 30.9M | 19.4M | — | — | — | — | — | — | — |
| Change in shares outstanding | +23.3% | +59.5% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −131.6% | −55.7% | −46.5% | −154.3% | −61.0% | −41.6% | — | −351.5% | −380.9% | — |
| Return on assets (ROA) | −104.9% | −49.4% | −40.6% | −123.8% | −52.2% | −31.4% | −210.0% | −194.5% | −191.4% | −436.2% |
| Return on tangible assets | −143.5% | −61.0% | −23.7% | −280.9% | −64.0% | −16.6% | −359.9% | −175.5% | −127.2% | −276.3% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −600.1% |
| Financial health | ||||||||||
| Total debt | $1.0M | $1.5M | $2.1M | $2.7M | $3.0M | $3.7M | $4.1M | $66,600 | $65,800 | $69,100 |
| Cash & short-term investments | $45.4M | $80.5M | $119.2M | $16.6M | $68.1M | $103.1M | $1.4M | $13.1M | $10.4M | $2.9M |
| Net debt | −$44.4M | −$79.0M | −$117.0M | −$13.9M | −$65.1M | −$99.4M | $2.7M | −$13.0M | −$10.3M | −$2.9M |
| Debt / equity | 0.03 | 0.02 | 0.02 | 0.22 | 0.05 | 0.04 | — | 0.01 | 0.01 | 0.11 |
| Debt / assets | 0.02 | 0.02 | 0.02 | 0.13 | 0.04 | 0.03 | 0.71 | 0.00 | 0.01 | 0.02 |
| Current ratio | 3.67 | 6.51 | 23.55 | 3.83 | 12.32 | 24.85 | 0.57 | 4.87 | 7.56 | 2.47 |
| Quick ratio | 3.67 | 6.51 | 23.55 | 3.99 | 11.89 | 24.63 | 0.57 | 4.79 | 7.56 | 2.47 |
| Interest coverage | — | — | — | — | -205.9 | — | — | — | — | — |
| Working capital | $34.1M | $69.5M | $115.5M | $12.9M | $65.2M | $99.9M | −$1.2M | $10.9M | $9.6M | $2.0M |
| Invested capital | −$8.8M | −$8.6M | −$2.8M | −$1.8M | −$381,300 | −$7.4M | −$3.0M | −$6.0M | −$3.4M | −$2.2M |
| Tangible asset value | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M | $92.0M | −$5.7M | $7.1M | $6.9M | $615,800 |
| Net current asset value | $33.9M | $68.1M | $111.3M | $8.5M | $61.1M | $87.8M | −$9.9M | $6.7M | $6.7M | $281,500 |
| Graham net-net per share | $0.85 | $2.15 | $5.67 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $867.0M | $945.1M | $1.39B | $1.26B | $1.14B | $1.03B | $1.26B |
| Share buybacks (net) | — | — | — | $173,900 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 11.9% | 39.3% | 5.7% | — | 18.1% | 25.3% | 82.5% | — | — | 19.1% |
| Capex / depreciation | 0.21 | 0.30 | 0.11 | 0.40 | 0.28 | 2.34 | 2.67 | 1.91 | 0.02 | 4.36 |
| Stock-based compensation / revenue | 315.0% | 887.9% | 205.1% | — | 313.9% | 211.7% | 1,144.0% | — | — | 68.1% |
| R&D / revenue | 4,332.1% | 8,101.9% | 1,881.8% | — | 3,193.1% | 1,094.6% | 3,989.6% | — | — | 416.3% |
| SG&A / revenue | 1,451.6% | 3,515.2% | 1,321.7% | — | 1,194.7% | 651.5% | 1,976.0% | — | — | 469.4% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | 458.6 | 13.6 | — | — | — | — |
| Days of inventory on hand | — | — | — | 614.8 | 760.1 | — | — | 461.1 | — | — |
| Days payables outstanding | — | 632.3 | 1,291.6 | 1,872.8 | 805.2 | — | 5,118.5 | 4,503.9 | 4,665.4 | 28.8 |
| Cash conversion cycle (days) | — | — | — | — | 413.4 | — | — | — | — | — |
| Receivables turnover | — | — | — | 0.00 | 0.80 | 26.83 | — | 0.00 | — | — |
| Payables turnover | 0.00 | 0.58 | 0.28 | 0.19 | 0.45 | 0.00 | 0.07 | 0.08 | 0.08 | 12.69 |
| Inventory turnover | — | — | — | — | 0.48 | 0.00 | — | 0.79 | — | — |
| Asset turnover | 0.02 | 0.00 | 0.01 | 0.00 | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 | 0.53 |
| Average receivables | — | — | — | $1.8M | $1.4M | $40,600 | — | $300,000 | — | — |
| Average payables | $1.1M | $1.1M | $2.0M | $2.6M | $1.8M | $1.3M | $1.4M | $1.1M | $1.0M | $901,650 |
| Average inventory | — | — | — | $858,700 | $1.7M | $942,200 | — | $115,200 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VTGN's annual financial statements (latest annual report filed June 15, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VTGN valuation and financial ratios
VistaGen Therapeutics earned a return on equity of −131.6% in fiscal 2026. It ended the year with $1.0 million of debt and $45.4 million in cash and short-term investments, a net cash position of $44.4 million.
See the VTGN income statement, the VTGN chart for price history, or the VTGN stock overview for the latest quote and news.
VTGN key metrics FAQ
What is VistaGen Therapeutics's return on equity?
VistaGen Therapeutics's return on equity (ROE) was −131.6% in fiscal 2026: net income of -$69.7 million on average shareholders' equity of $53.0 million.
How much debt does VistaGen Therapeutics have?
VistaGen Therapeutics had total debt of $1.0 million at the end of fiscal 2026, a debt-to-equity ratio of 0.03 and more cash than debt.
What is VistaGen Therapeutics's free cash flow yield?
VistaGen Therapeutics generated -$66.4 million of free cash flow in fiscal 2026, a free cash flow yield of −306.1% on its market value at year-end ($21.7 million).
What is VistaGen Therapeutics's current ratio?
VistaGen Therapeutics's current ratio was 3.67 at the end of fiscal 2026: current assets were 3.67 times current liabilities.